Abstract
The CMV promoter drives high transgene expression and is one of the most commonly used promoters for gene transfer. Tissue-specific mammalian promoters provide an alternative, and it would be useful to have a system to directly compare them to viral promoters free from potential confounding vector-related effects. In this study, we describe how electroporation after subretinal injection of plasmid DNA can be used to perform comparative quantitative analysis of promoter activities. Luciferase assay of eyecup homogenates was carried out after coinjection/electroporation of pGL2, a plasmid containing the promoter fragment of interest coupled to the firefly luciferase gene, and pRL-CMV, a plasmid containing the CMV promoter coupled to the Renilla luciferase gene for normalization. This technique was used to compare activity of different fragments of the 5′-upstream region of the vitelliform macular dystrophy 2 (VMD2) gene, which is selectively expressed in the retinal pigmented epithelial (RPE) cells, and results indicated positive regulatory elements between −104 and −154 bp and between −424 and −585 bp. Addition of a fragment from intron 1 reduced the activity of the −585/+38 bp fragment by 75%. Deletion analysis implicated a 342 bp region near the 5′-end of intron 1 in the repression. Results of transient transfections in two cell lines that constitutively express VMD2 were similar, and results in transgenic mice were consistent, providing validation for promoter analysis by in vivo electroporation. We then explored the time course of expression of the −585/+38 VMD2 promoter fragment and found that compared to cassettes driven by CMV or SV40 promoters, which showed peak luciferase activity on day 2 followed by a rapid decrease in activity, the VMD2 promoter fragment showed lower activity initially, but the activity was sustained for up to 56 days (longest time point measured). A promoter fragment from another RPE-specific gene, Rpe65, showed a similar pattern of sustained expression for at least 112 days. These data indicate that nonviral gene transfer can be used to quantitatively evaluate the activity of promoter fragments independent of influence from viral vectors. A potentially important finding using this new technique is the demonstration that relatively sustained passenger gene expression can be achieved with nonviral gene transfer using mammalian rather than viral promoters.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Campochiaro PA, Hackett SF . Corneal endothelial cell matrix promotes expression of differentiated features of retinal pigmented epithelial cells: implication of laminin and basic fibroblast growth factor as active components. Exp Eye Res 1993; 57: 539–547.
Kachi S, Oshima Y, Esumi N, Kachi M, Rogers B, Zack DJ et al. Nonviral ocular gene transfer. Gene Therapy 2005; 12: 843–851.
Esumi N, Oshima Y, Li Y, Campochiaro PA, Zack DJ . Analysis of the VMD2 promoter and implication of E-Box binding factors in its regulation. J Biol Chem 2004; 279: 19064–19073.
Biedler JL, Spengler BA . A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lines in culture. J Natl Cancer Inst 1976; 57: 683–695.
Davis AA, Berstein PS, Bok D, Turner J, Nachtigal M, Hunt RC . A human retinal pigment epithelial cell line that retains epithelial characteristics after prolonged culture. Invest Ophthalmol Vis Sci 1995; 36: 955–964.
Mori K, Gehlbach P, Ando A, Wahlin K, Gunther V, McVey D et al. Intraocular adenoviral vector-mediated gene transfer is increased in proliferative retinopathies. Invest Ophthalmol Vis Sci 2002; 43: 1610–1615.
Reichel MB, Ali RR, Thrasher AJ, Hunt DM, Bhattacharya SS, Baker D . Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Therapy 1998; 5: 1038–1046.
Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL . Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992; 92: 2581–2584.
Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM . Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407–4411.
Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM . Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401–1405.
Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM . Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395–404.
Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS . Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019–2029.
Fedor MJ, Daniell E . Acetylation of histone-like proteins of adenovirus type 5. J Virol 1980; 35: 637–643.
Ghazal P, DeMattei C, Giulietti E, Kliewer SA, Umesono K, Evans RM . Retinoic acid receptors initiate induction of the cytomegalovirus enhancer in embryonal cells. Proc Natl Acad Sci USA 1992; 89: 7630–7634.
Gaetano C, Catalano A, Palumbo R, Illi B, Orlando G, Ventoruzzo G et al. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Therapy 2000; 7: 1624–1630.
Brough DE, McVey D, Hsu C, Wei L, King CR . Activation of gene expression from silenced adenovector genomes. Invest Ophthalmol Vis Sci 2004; 45: E-abstract 3484.
Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Therapy 2001; 8: 819–827.
Hartigan-O'Connor D, Kirk CJ, Crawford R, Mule JJ, Chamberlain JS . Immune evasion by muscle-specific expression in dystrophic muscle. Mol Ther 2001; 4: 525–533.
Zhang J, Ramesh N, Chen Y, Li Y, Dilley J, Working P et al. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res 2002; 62: 3743–3750.
Sakkonen K, Hemminki A . Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004; 4: 683–696.
Boulanger A, Liu S, Henningsgaard AA, Yu S, Redmond TM . The upstream region of the Rpe65 gene confers retinal pigment epithelium-specific expression in vivo and in vitro and contains critical octamer and E-box binding sites. J Biol Chem 2000; 275: 31274–31282.
Acknowledgements
This study was supported by EY05951, EY12609, and core Grant P30EY1765 from the NEI; the Macula Vision Research Foundation, an unrestricted grant from Research to Prevent Blindness, and Dr and Mrs William Lake. PAC is the George S and Dolores Dore Eccles Professor of Ophthalmology. DJZ is the Guerrieri Professor of Genetic Engineering and Molecular Ophthalmology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kachi, S., Esumi, N., Zack, D. et al. Sustained expression after nonviral ocular gene transfer using mammalian promoters. Gene Ther 13, 798–804 (2006). https://doi.org/10.1038/sj.gt.3302700
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302700
Keywords
This article is cited by
-
Suprachoroidal Electrotransfer: A Nonviral Gene Delivery Method to Transfect the Choroid and the Retina Without Detaching the Retina
Molecular Therapy (2012)
-
Insulin expressed from endogenously active glucose-responsive EGR1 promoter in bone marrow mesenchymal stromal cells as diabetes therapy
Gene Therapy (2010)